Coria Laboratories Announces Acanya(TM) Gel Data Presentations at 67th American Academy of Dermatology Annual Meeting
the newly expanded dermatology division of Valeant Pharmaceuticals
International (NYSE: VRX), today announced six data presentations on Acanya
Gel at the 67th Annual Meeting of the American Academy of Dermatology (AAD),
taking place
presentations demonstrate the efficacy and safety of once daily Acanya Gel
(clindamycin phosphate 1.2% and benzoyl peroxide 2.5%) in treating patients
with moderate to severe acne vulgaris.
“Data to be presented at AAD will confirm the superior efficacy of Acanya
Gel over active ingredients and vehicle for both inflammatory and
non-inflammatory acne lesions, while showing favorable safety and tolerability
in patients with moderate to severe acne vulgaris,” said
president of Coria Laboratories. “Other highlights include a presentation on
how Acanya Gel was developed to enhance the bioavailability of benzoyl
peroxide while minimizing the risk of skin irritation, a discussion on Acanya
Gel’s role in effective management of adolescent acne, and a session on the
importance of Patient Reported Outcomes in the treatment of acne vulgaris.”
Following are details for each poster presentation. (All times are Pacific
Standard Time. All presentations are located in Moscone Center North, Hall E)
Abstract #717
Poster Discussion: Can delivery be enhanced and skin irritation minimized
using a lower concentration of benzoyl peroxide in a fixed combination
product?
Presenter:
Vegas, Nevada
Abstract #718
Poster Discussion: Assessing efficacy of a fixed combination of
clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%)
aqueous gel in the treatment of severe acne
Presenter:
Abstract #724
Poster Discussion: Patient reported outcomes using a fixed combination
clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%)
aqueous gel for the treatment of moderate to severe acne in 2,813 subjects
Presenter:
Abstract #738
Poster Discussion: Efficacy of a fixed combination clindamycin phosphate
(1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate
to severe acne
Presenter:
Abstract #739
Poster Discussion: Safety and cutaneous tolerability of a fixed
combination clindamycin phosphate (1.2%) and low concentration benzoyl
peroxide (2.5%) aqueous gel for the once-daily treatment of moderate to severe
acne
Presenter:
Abstract #740
Poster Discussion: Managing moderate to severe acne in adolescents:
Benefits of a fixed combination clindamycin phosphate (1.2%) and low
concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1,755
subjects
Presenter:
About Acanya Gel
Acanya Gel is the only FDA-approved fixed combination antibiotic and
benzoyl peroxide (BPO) medication for once-daily treatment of both
non-inflammatory and inflammatory lesions of acne. Formulated in an
aqueous-based, alcohol-free gel, Acanya Gel was optimized to provide enhanced
bioavailability of BPO, creating an effective and well tolerated product. In
pivotal Phase III clinical trials, Acanya Gel showed superior efficacy to the
vehicle gel and either individual active ingredient, while demonstrating
excellent tolerability and very high patient satisfaction scores.
Acanya Gel was developed by Arcutis Pharmaceuticals, now a part of Coria
Laboratories, a division of Valeant Pharmaceuticals International. Acanya Gel
is protected by two U.S. Patents and has pending patent applications. More
information about Acanya Gel can be obtained at http://www.AcanyaGel.com.
Indication and Important Safety Information for Acanya Gel
Acanya Gel (clindamycin phosphate 1.2% and benzoyl peroxide 2.5%) is
indicated for the topical treatment of acne vulgaris in patients 12 years of
age or older. In controlled clinical trials, the following application-site
adverse reactions occurred in less than 0.2% of patients treated with Acanya
Gel: application-site pain (0.1%), application-site exfoliation (0.1%), and
application-site irritation (0.1%). Patients are advised to avoid applying in
mouth, eyes, or nose or on lips, and to minimize sun exposure following the
application of Acanya Gel.
About Coria Laboratories
Coria Laboratories is the dermatology division of Valeant Pharmaceuticals
International. With its acquisition of Coria Laboratories Ltd. in
2008
pharmaceutical products focused on medical dermatology. Coria Laboratories
combines a commercial organization with management expertise, a proven sales
force and a goal of developing and marketing innovative products, positioning
Coria Laboratories for dermatology industry leadership going forward. Coria
Laboratories is committed to establishing a tradition of unparalleled service
to the dermatology community, with the critical goal of supporting
dermatologists and their practices through greater patient satisfaction with
therapy. For more information, please visit http://www.corialabs.com.
About Valeant Pharmaceuticals:
Valeant Pharmaceuticals International (NYSE:VRX) is a multinational
specialty pharmaceutical company that develops and markets a broad range of
pharmaceutical products primarily in the areas of neurology and dermatology.
More information about Valeant can be found at http://www.valeant.com.
FORWARD-LOOKING STATEMENTS:
This press release contains forward-looking statements, including, but not
limited to, statements regarding the efficacy of Acanya and favorable safety
profile. These statements are based upon the current expectations and beliefs
of management and are subject to certain risks and uncertainties that could
cause actual results to differ materially from those described in the
forward-looking statements. These risks and uncertainties include, but are not
limited to, risks and uncertainties related to the data to be presented at AAD
that will confirm the superior efficacy of Acanya Gel and other risks and
uncertainties discussed in the company’s annual report or Form 10-K for the
years ended
to caution the reader that these factors are among the factors that could
cause actual results to differ materially from the expectations described in
the forward-looking statements. Valeant also cautions the reader that undue
reliance should not be placed on any of the forward-looking statements, which
speak only as of the date of this release. The company undertakes no
obligation to update any of these forward-looking statements to reflect events
or circumstances after the date of this release or to reflect actual outcomes.
(Logo: http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO)
Contacts:
Investors: Media:
Laurie W. Little Carole Melis
949-461-6002 650-342-5686
laurie.little@valeant.com clmcomm1@gmail.com
SOURCE Valeant Pharmaceuticals International